Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Roivant Sciences lays off 12% of workers 

By Brian Buntz | November 14, 2022

RoivantThe biopharma Roivant Sciences (Nasdaq:ROIV) has decided to cut roughly 100 employees from its 891-person workforce.

According to CEO Matt Gline, the company decided on the reorganization to allow sufficient cash runway to last until the second half of 2025.

In the quarter that ended September 30, 2022, the company had a net loss of $315.9 million compared to a net loss of $225.6 million for the same period in 2021.

The company had $1.6 billion in consolidated cash, cash equivalents and restricted cash on September 30, 2022.

Endpoints News first reported on the layoffs.

The company also announced a $150 million primary and secondary offering to generate $100 million in gross primary proceeds.

Roivant is the parent company of a dozen smaller companies.

Roivant was the originator of Urovant, a urology-focused business that developed vibegron, an oral β3-adrenergic agonist for overactive bladder. Sumitomo Dainippon Pharma eventually agreed to take control of the company in 2020.

The company’s dermatology subsidiary Dermavant won FDA approval in May for the psoriasis drug Vtama.

Vtama has become the most widely prescribed branded topical for psoriasis.

Since Roivant Sciences launched the drug, physicians have written more than 54,000 prescriptions for the medication, which generated $5 million in net product revenue in the second quarter of 2022.

“We are really pleased with how this launch is going,” said CEO Matt Gline in a call with investors and financial analysts.

“We’re focused on becoming the mainstay of therapy and ultimately supplanting steroids” in treating psoriasis, Gline added.

The founder of Roivant, Vivek Ramaswamy, resigned his post as CEO to become executive chairman of its board in January 2021. The company’s former chief financial officer, Matt Gline, assumed the CEO role that same month.

The company has several clinical trials underway in inflammation and immunology, including for the TYK2/JAK1 inhibitor brepocitinib and batoclimab, a monoclonal antibody targeting the neonatal Fc receptor.

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Genentech roche
Roche, Genentech to build $700M drug manufacturing plant in North Carolina
These are the logos of Otsuka Medical and ICU Medical.
ICU Medical, Otsuka Pharmaceutical Factory launch joint IV supply chain venture
Amgen
Amgen to spend $900M to expand U.S. biopharma manufacturing
Roche
Roche to invest $50B in U.S. over next five years
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE